Adapthealth Corp Q3 2026 Earnings: Miss on Both Revenue and EPS
Adapthealth Corp (AHCO) delivered disappointing third-quarter 2026 results, reporting earnings per share of $0.06 versus analyst estimates of $0.17, representing a significant 65.40% negative surprise. The durable medical equipment provider also fell short on revenue, generating $740.31 million compared to expectations of $865.60 million, marking a 14.47% revenue miss that signals broader challenges in the healthcare equipment sector.
Durable Medical Equipment Provider Faces Headwinds
Adapthealth Corp operates as one of the nation’s largest providers of home medical equipment, specializing in sleep therapy equipment, diabetes management supplies, and other durable medical equipment through a network of over 300 locations across 46 states. The company serves approximately 4 million patients through both direct-pay and insurance reimbursement models, with sleep apnea therapy representing roughly 60% of total revenue and diabetes supplies accounting for approximately 25% of sales.
Earnings Performance Shows Sharp Decline
The $0.06 actual EPS represents a substantial decline from the company’s performance in recent quarters, with the 65.40% negative surprise marking one of the largest earnings misses in Adapthealth’s recent history. Revenue of $740.31 million, while still substantial, reflects ongoing pressures from Medicare reimbursement rate adjustments and increased competition in the home healthcare market. The revenue shortfall of $125.29 million suggests the company may be losing market share or facing pricing pressures across its key product categories.
Compared to the same quarter in 2025, when Adapthealth reported revenue of approximately $820 million, the current quarter shows a year-over-year decline of roughly 9.7%. This decline comes despite the company’s previous guidance suggesting modest growth for 2026, indicating that market conditions have deteriorated more rapidly than management anticipated.
Operational Challenges and Market Dynamics
The earnings miss appears to stem from multiple factors affecting the durable medical equipment industry, including ongoing Medicare Advantage plan changes that have reduced reimbursement rates for sleep therapy equipment by an estimated 8-12% industry-wide. Additionally, increased competition from online retailers and direct-to-consumer manufacturers has pressured margins, particularly in the diabetes supply segment where generic alternatives have gained market share.
Adapthealth’s gross margin likely compressed during the quarter due to these reimbursement pressures and the company’s need to maintain competitive pricing. The company has been investing in technology infrastructure and expanding its patient management capabilities, which may have contributed to higher operating expenses that weren’t fully offset by revenue growth.
Forward Outlook and Market Reaction
Management has not yet provided updated guidance for the remainder of 2026, though industry analysts expect continued pressure from Medicare reimbursement changes scheduled to take effect in early 2027. The company’s ability to maintain its patient base while navigating these reimbursement headwinds will be critical for future performance.
The broader home healthcare sector has faced similar challenges, with several competitors reporting margin compression and slower patient acquisition rates. Adapthealth’s scale advantage through its 300+ location network may provide some protection, but the company will need to demonstrate improved operational efficiency to restore investor confidence.
Post-market trading data was not immediately available, though the significant earnings miss is likely to pressure the stock when markets open. Analysts may revise their full-year 2026 estimates downward following these results, particularly given the magnitude of both the EPS and revenue misses.
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions.